Voyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings Results

Voyager Therapeutics (NASDAQ:VYGR) announced its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.20, Zacks reports. The firm had revenue of $29.58 million for the quarter, compared to the consensus estimate of $11.52 million. Voyager Therapeutics had a return on equity of 3.59% and a net margin of 6.28%. During the same period in the previous year, the business earned ($0.51) EPS.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR traded down $0.21 during trading on Friday, hitting $7.05. 39,356 shares of the company were exchanged, compared to its average volume of 681,136. The company has a market cap of $383.45 million, a PE ratio of -145.17 and a beta of 0.96. The stock has a 50 day moving average of $8.36 and a 200 day moving average of $8.39. Voyager Therapeutics has a 52-week low of $6.06 and a 52-week high of $11.72.

Analyst Ratings Changes

VYGR has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Wednesday, July 31st. Wedbush decreased their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday. Oppenheimer reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Voyager Therapeutics in a report on Wednesday, May 15th. Finally, StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.83.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.